Navigation Links
Organovo Rings Opening Bell On New York Stock Exchange
Date:7/15/2013

NEW YORK, July 15, 2013 /PRNewswire/ -- Organovo Holdings, Inc. (NYSE: ONVO), today rang the opening bell on the New York Stock Exchange (NYSE).  Organovo Holdings, Inc. shares began trading on the NYSE on Thursday, July 11, 2013, after qualifying as an NYSE MKT listing company.

"Organovo is proud to ring the opening bell on behalf of our employees, investors and all of our supporters, in recognition of our recent uplisting to the New York Stock Exchange.  This milestone is another important step forward for the company in our mission to advance the impact of 3D bioprinting in changing the shape of medical research and practice," said Keith Murphy, president and chief executive officer of Organovo Holdings, Inc.  "We found NYSE to have made an unparalleled commitment to providing a fertile platform for growth to early stage biotechnology companies, and we look forward to a great future on the exchange."

"As Scientific Founder of Organovo I am deeply moved by this latest success of the company," said Professor Gabor Forgacs of the University of Missouri-Columbia and Clarkson University.  "For a scientist, watching the progress of one's technology represents the ultimate dream come true, and it is rewarding to see the numerous nights spent in the academic lab, combined with the many long hours devoted by Organovo's team, creating realistic hope for many patients for improved quality of life."

The uplisting allows Organovo investors to utilize the trading, connectivity and routing technologies of the NYSE platform and offers superior price discovery, superior liquidity and reduced trading volatility.  Listed companies benefit from issuer-selected Designated Market Makers (DMM) that utilize world-class NYSE trading systems to discover and improve prices, dampen volatility, add liquidity and enhance value.  In addition, NYSE MKT-listed companies gain access to the brand visibility and are eligible for the issuer services enjoyed by the NYSE Euronext community. 

A video of the bell ringing ceremony can be found online at https://www.youtube.com/watch?v=jqCvThm17cg.

About Organovo Holdings, Inc.
Organovo designs and creates functional, three-dimensional human tissues for medical research and therapeutic applications. The Company is collaborating with pharmaceutical and academic partners to develop human biological disease models in three dimensions. These 3D human tissues have the potential to accelerate the drug discovery process, enabling treatments to be developed faster and at lower cost. In addition to numerous scientific publications, our technology has been featured in The Wall Street Journal, Time Magazine, The Economist, and numerous others. Organovo is changing the shape of medical research and practice. Learn more at www.organovo.com.

Safe Harbor Statement
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company's ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company's products and technology; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and the Company's business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in our filings with the SEC, including our transition report on Form 10-KT filed with the SEC on May 24, 2013.  You should not place undue reliance on these forward-looking statements, which speak only as of the date that they were made. These cautionary statements should be considered with any written or oral forward-looking statements that we may issue in the future. Except as required by applicable law, including the securities laws of the United States, we do not intend to update any of the forward-looking statements to conform these statements to reflect actual results, later events or circumstances or to reflect the occurrence of unanticipated events.


'/>"/>
SOURCE Organovo Holdings, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. OTC Markets Group Congratulates Organovo Holdings on Move to NYSE MKT
2. Organovo To List Common Stock On New York Stock Exchange MKT
3. Organovo Appoints Tamar D. Howson to Board of Directors
4. Organovo to Present at the 12th Annual Needham Healthcare Conference
5. Organovo Partners With ZenBio to Create 3D Tissue Models
6. Organovo Holdings, Inc. Investor Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com
7. Organovo Reports Q3 2012 Financial Results, Provides Business Update
8. Organovo To Present At Lazard Healthcare Conference
9. Organovo Holdings, Inc. to Webcast, Live, at RetailInvestorConferences.com on August 2nd
10. Organovo Announces Relocation and Commencement of Operations at Larger Facility
11. Organovo Announces Close of $15.2 Million Private Placement to Advance 3D Bioprinting for Medical Applications
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... Research and Markets has announced the ... to their offering. ... The Global Market for Bioproducts Should Reach ... a CAGR of 8.9%, This research report ... seven major product segments: bio-derived chemicals, biofuels, pharmaceuticals (biodrugs and ...
(Date:3/23/2017)... Mass. , March 23, 2017 /PRNewswire/ ... partner to global in vitro diagnostics manufacturers ... of the industry,s first multiplexed Inherited ... disease testing by next-generation sequencing (NGS). The ... were developed with input from industry experts ...
(Date:3/23/2017)...  BioPharmX Corporation (NYSE MKT: BPMX), a specialty ... today reported financial results for the quarter and ... an update on the company,s clinical development efforts ... are pleased to report that last year was ... Anja Krammer. "We achieved key clinical milestones and ...
(Date:3/23/2017)... March 23, 2017 Kineta, Inc., a ... novel therapies in immuno-oncology, today announced the discovery ... molecule compounds that activate interferon response factor 3 ... demonstrate immune-mediated tumor regression in a murine colon ... who demonstrated complete tumor regression to initial drug ...
Breaking Biology Technology:
(Date:3/6/2017)... MATEO, Calif. , March 6, 2017 /PRNewswire/ ... marketing and sales technology, today announced Predictive Sales ... solution for infusing actionable sales intelligence into Salesforce. ... to automatically enable their sales organizations with deep ... messages that allow for intelligent engagement. Predictive Sales ...
(Date:3/1/2017)... 1, 2017  Aware, Inc. (NASDAQ: AWRE), a leading ... Richard P. Moberg has resigned, effective March 3, ... Financial Officer and Treasurer of Aware citing a desire ... a member of the Board of Directors of Aware. ... Executive Officer and co-President, General Counsel has been named ...
(Date:2/26/2017)... Feb. 25, 2017  Securus Technologies, a leading ... for public safety, investigation, corrections and monitoring, announces ... Reentry. "Too often, too many offenders ... county jails are trying to tackle this ongoing ... friends and family members. While significant steps are underway, ...
Breaking Biology News(10 mins):